Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinemia, pituitary or hypothalamic tumours. Patients w/ clinically significant systemic diseases where pregnancy could lead to worsening of the condition. Possible ovarian hyperstimulation syndrome (OHSS); monitor stimulation cycles by ultrasound scans & estradiol measurements to early identify risk factors. Increased incidence of multiple pregnancy & births; pregnancy loss by miscarriage or abortion. Increased risk for ectopic pregnancy in women w/ history of tubal disease. Slightly higher prevalence of congenital malformations after ART. Women w/ recent thromboembolic disease or those w/ generally recognised risk factors for thromboembolic events (eg, personal or family history). Possible ovarian & other reproductive system neoplasms. May potentially lead to a false +ve pregnancy test; may interfere w/ immunological determination of serum or urinary HCG for up to 10 days. Contains Na <1 mmol/dose. No indication for use during pregnancy. Not indicated during breastfeeding.
Sign Out
